MOLECULAR TEMPLATES INC (MTEM) Stock Fundamental Analysis
USA - NASDAQ:MTEM - US6085502085 - Common Stock
0.1072 USD
-0.03 (-23.43%)
0.1113 USD
+0 (+3.82%)
Overall MTEM gets a fundamental rating of 2 out of 10. We evaluated MTEM against 533 industry peers in the Biotechnology industry. While MTEM seems to be doing ok healthwise, there are quite some concerns on its profitability. MTEM has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
MTEM had negative earnings in the past year.
In the past year MTEM has reported a negative cash flow from operations.
In the past 5 years MTEM always reported negative net income.
In the past 5 years MTEM always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of MTEM (-58.52%) is comparable to the rest of the industry.
MTEM has a worse Return On Equity (-219.70%) than 69.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.52% | ||
| ROE | -219.7% | ||
| ROIC | N/A |
ROA(3y)-53.73%
ROA(5y)-55.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MTEM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MTEM does not have a ROIC to compare to the WACC, probably because it is not profitable.
MTEM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MTEM has been increased compared to 5 years ago.
There is no outstanding debt for MTEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -25.30, we must say that MTEM is in the distress zone and has some risk of bankruptcy.
MTEM's Altman-Z score of -25.30 is on the low side compared to the rest of the industry. MTEM is outperformed by 89.77% of its industry peers.
MTEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -25.3 |
ROIC/WACCN/A
WACC10.24%
2.3 Liquidity
MTEM has a Current Ratio of 1.56. This is a normal value and indicates that MTEM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.56, MTEM is doing worse than 81.87% of the companies in the same industry.
MTEM has a Quick Ratio of 1.56. This is a normal value and indicates that MTEM is financially healthy and should not expect problems in meeting its short term obligations.
MTEM's Quick ratio of 1.56 is on the low side compared to the rest of the industry. MTEM is outperformed by 80.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.56 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 78.35% over the past year.
MTEM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -49.41%.
The Revenue has been growing by 33.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)78.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.84%
Revenue 1Y (TTM)-49.41%
Revenue growth 3Y44.86%
Revenue growth 5Y33.95%
Sales Q2Q%-91.67%
3.2 Future
Based on estimates for the next years, MTEM will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.70% on average per year.
MTEM is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.69% yearly.
EPS Next Y-92.81%
EPS Next 2Y-24.36%
EPS Next 3Y-21.57%
EPS Next 5Y-19.7%
Revenue Next Year-78.76%
Revenue Next 2Y-85.29%
Revenue Next 3Y-46.28%
Revenue Next 5Y-10.69%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MTEM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTEM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MTEM's earnings are expected to decrease with -21.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.36%
EPS Next 3Y-21.57%
5. Dividend
5.1 Amount
No dividends for MTEM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.1072
-0.03 (-23.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners56.12%
Inst Owner Change2281000%
Ins Owners3.96%
Ins Owner Change0%
Market Cap705.38K
Revenue(TTM)25.47M
Net Income(TTM)-15.62M
Analysts82.86
Price Target18.36 (17026.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.16%
Min EPS beat(2)16.26%
Max EPS beat(2)110.06%
EPS beat(4)4
Avg EPS beat(4)48.67%
Min EPS beat(4)16.26%
Max EPS beat(4)110.06%
EPS beat(8)7
Avg EPS beat(8)48.91%
EPS beat(12)10
Avg EPS beat(12)36.51%
EPS beat(16)12
Avg EPS beat(16)-1.05%
Revenue beat(2)2
Avg Revenue beat(2)57.36%
Min Revenue beat(2)30.42%
Max Revenue beat(2)84.31%
Revenue beat(4)3
Avg Revenue beat(4)68.38%
Min Revenue beat(4)-11.54%
Max Revenue beat(4)170.33%
Revenue beat(8)6
Avg Revenue beat(8)235.75%
Revenue beat(12)8
Avg Revenue beat(12)154.87%
Revenue beat(16)8
Avg Revenue beat(16)104.62%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.03 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.1 | ||
| P/tB | 0.1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.7
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.64
OCFYN/A
SpS3.87
BVpS1.08
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.52% | ||
| ROE | -219.7% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-53.73%
ROA(5y)-55.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.56 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | -25.3 |
F-Score4
WACC10.24%
ROIC/WACCN/A
Cap/Depr(3y)35.57%
Cap/Depr(5y)222.6%
Cap/Sales(3y)8.96%
Cap/Sales(5y)21.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.84%
EPS Next Y-92.81%
EPS Next 2Y-24.36%
EPS Next 3Y-21.57%
EPS Next 5Y-19.7%
Revenue 1Y (TTM)-49.41%
Revenue growth 3Y44.86%
Revenue growth 5Y33.95%
Sales Q2Q%-91.67%
Revenue Next Year-78.76%
Revenue Next 2Y-85.29%
Revenue Next 3Y-46.28%
Revenue Next 5Y-10.69%
EBIT growth 1Y57.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.4%
OCF growth 3YN/A
OCF growth 5YN/A
MOLECULAR TEMPLATES INC / MTEM FAQ
What is the ChartMill fundamental rating of MOLECULAR TEMPLATES INC (MTEM) stock?
ChartMill assigns a fundamental rating of 2 / 10 to MTEM.
Can you provide the valuation status for MOLECULAR TEMPLATES INC?
ChartMill assigns a valuation rating of 0 / 10 to MOLECULAR TEMPLATES INC (MTEM). This can be considered as Overvalued.
Can you provide the profitability details for MOLECULAR TEMPLATES INC?
MOLECULAR TEMPLATES INC (MTEM) has a profitability rating of 0 / 10.
Can you provide the financial health for MTEM stock?
The financial health rating of MOLECULAR TEMPLATES INC (MTEM) is 5 / 10.